AI and Patent Strategy in Life Sciences – Part 4: AI Is Coming for Patent Surprise

By Daniel J. Holmander and Michel “Mike” Morency, Ph.D. on July 13, 2026

Part 4: How recurring freedom-to-operate monitoring may help life-science companies and investors find patent risk before it becomes litigation leverage, diligence friction, or exit risk.

Introduction

Patent trolls have long understood something important about patent litigation: surprise creates leverage.

A company builds a product, enters the market, imports components, raises capital, signs customers, or prepares for exit. Then a patent owner appears and claims that something the business depends on – a product feature, device component, assay, manufacturing process, supply-chain element, software layer, or clinical workflow – infringes its patent.

By that point, the patent issue is no longer just legal. It is commercial. Customers, suppliers, investors, regulatory plans, manufacturing dependencies, and transaction timelines may already rely on the accused technology. Even a disputed claim can create immediate pressure: legal cost, business distraction, damages exposure, the threat of an injunction or import ban, investor concern, and settlement leverage for the patent owner.

AI will not end patent litigation. But it may diminish patent surprise.

For life-science companies and investors, that may be one of the most important AI-driven changes in patent strategy. Recurring freedom-to-operate (FTO) monitoring – the ongoing review of whether products may run into someone else’s patents – can surface patent risk before the business has become dependent on the technology at issue.

Patent risk found early is a business issue. Patent risk found late becomes litigation leverage.

Why This Is Part 4

This is the fourth and final article in our series on AI and patent strategy in life sciences. Part 1 explained why better AI tools do not replace better patent judgment in diligence and opinions. Part 2 examined how AI makes weak patent portfolios easier to test during prosecution. Part 3 explored how AI may enable more continuous diligence in transactions and licensing.

This installment turns to where patent risk becomes most expensive: litigation, patent-office challenges, and import disputes – and why the companies that find risk first tend to fare best.

Patent Surprise Is a Business Problem, Not a Legal Doctrine

You will not find “patent surprise” in any statute. It is shorthand for a familiar pattern: a company discovers third-party patent risk only after it has committed meaningful resources to a product, platform, process, supply chain, financing, partnership, or market strategy. By the time the patent appears, the company has fewer practical options.

For investors, this is not an abstract legal issue. It is a diligence issue, a valuation issue, and sometimes an exit issue. A life-science company may have strong science, promising data, and a credible market opportunity – but if third-party patent risk surfaces late, the economics can change quickly. The issue may affect valuation, deal terms, indemnities, product timing, licensing leverage, reserves, or post-closing remediation.

Example – Sequenom, Ariosa, and non-invasive prenatal testing. Sequenom licensed a patent on using cell-free fetal DNA in maternal blood for prenatal diagnosis. After Sequenom launched its test, competitors marketed similar non-invasive prenatal tests, Sequenom sent infringement letters, and Ariosa and others went to court first, asking a judge to declare the patent invalid. The Federal Circuit ultimately held the asserted claims ineligible for patent protection. The point is not that AI would have prevented that dispute. The point is that a valuable diagnostic market developed quickly, competitors entered, and patent risk became a central business issue for everyone involved.

Innocent Infringement Is Often a Timing Problem

Direct patent infringement does not require bad intent. Under 35 U.S.C. 271(a), a company can directly infringe by making, using, selling, offering to sell, or importing a patented invention without permission during the patent’s term; intent to infringe is not an element of direct infringement.

That is one reason patent disputes are so disruptive. A company may believe it is developing its own technology, relying on trusted suppliers, or using standard industry tools. Later, a patent owner claims the product falls within patent claims the company never knew existed. In many cases, the issue is not copying. It is late discovery – and AI may reduce the amount of risk that stays hidden until after launch, scale, financing, importation, or exit.

Example – 10x Genomics, Bio-Rad, and single-cell analysis. This litigation shows how patent risk can emerge around a high-growth life-science platform after substantial commercial development. A Delaware jury found that 10x Genomics infringed University of Chicago patents exclusively licensed to Bio-Rad, awarding roughly $24 million plus an ongoing royalty; the appeals court upheld the verdict, and the companies eventually settled their broader disputes. For investors, the lesson is clear: the accused technology was not a side feature. It was central to a platform company’s commercial story.

The Old Tools Were Blunt. AI May Make Them More Precise.

Companies have never simply ignored patent surprise. They conduct FTO reviews before major milestones. They monitor competitor filings, build defensive patent portfolios, cross-license, acquire patents for counterclaim leverage, buy insurance, and join defensive patent networks.

Those tools exist because patent surprise is expensive. But many are broad, costly, episodic, or reactive. They rarely tell a management team something as specific as: this claim reads on this product feature, this pending application could issue against this component, this design-around window is closing.

The CRISPR patent wars illustrate how tangled the landscape can be even for sophisticated players. The Broad Institute, UC Berkeley, and others have fought for years over foundational CRISPR rights, and companies commercializing the technology may need licenses from more than one institution. When even the ownership of core rights is contested, occasional reviews struggle to keep up.

AI Changes the Economics of FTO

FTO analysis has historically been episodic for a simple reason: meaningful review is expensive and time-consuming. A company might commission one before a financing, a launch, or an acquisition. But products change. Claims change. Competitors file continuations – follow-on applications that can generate new claims from an old filing. Suppliers shift, product variants emerge, manufacturing processes evolve, and software or data layers are added. A single FTO review goes stale.

AI-assisted tools may make FTO continuous rather than occasional. They can monitor competitor patents and pending applications, track claim amendments, compare claims to product features, rank potentially relevant patents, summarize prosecution histories, and flag issues for attorney review.

Early research supports that division of labor. AI tools show promise at retrieving relevant patents and prior art and pinpointing the passages that matter, while still struggling with legal judgments such as novelty and non-obviousness. In short: AI can help find and organize patent risk. It does not decide what the risk means. That still requires legal judgment, which is why continuous monitoring changes the cost of finding risk, not the need for a legal opinion.

Earlier Discovery Creates Better Options

When patent risk is discovered late, options narrow. The product is launched. Customers depend on it. Manufacturing is locked in. A financing is underway, or a buyer is mid-diligence.

When risk is discovered early, the company can choose: design around the patent, seek a license, monitor the patent family, challenge the patent, adjust the product roadmap, change suppliers, reserve for the risk, or disclose the issue and negotiate before litigation pressure builds. A license negotiated before product dependence looks very different from a license negotiated after launch, customer adoption, manufacturing lock-in, or an active financing process.

For investors, the question is not simply whether a company has patents. It is whether the company has identified third-party patents that could block, tax, delay, or disrupt the value story. Recurring AI-assisted FTO does not eliminate those risks. It may allow them to be found before they become leverage for someone else.

Litigation, PTAB, and ITC Posture May Change

If AI diminishes patent surprise, disputes may become less about ambush and more about response. The fight will not be only about whether the accused product infringes. Increasingly, it will be about what the company knew, when it knew it, and what it did next.

That matters for damages. Courts may increase patent damages up to three times the amount found or assessed, and willfulness remains a critical issue in evaluating enhanced-damages risk. Earlier discovery therefore cuts both ways: it reduces exposure if the company responds responsibly – by designing around, obtaining legal advice, seeking a license, documenting a good-faith position, or challenging the patent – but it creates risk if the company spots a problem and ignores it.

Patent-office challenges may also move earlier. The Patent Trial and Appeal Board (PTAB) allows a company to challenge a patent’s validity through inter partes review, a focused patent-office proceeding limited to certain prior-art-based challenges. If a problematic patent is spotted before litigation begins, there is time to evaluate whether it can be challenged, designed around, licensed, monitored, or addressed in deal terms.

Import risk may become easier to spot, too. In Section 337 proceedings, imported articles that infringe a valid and enforceable U.S. patent can create exclusion risk, provided the statutory domestic-industry requirements are met. For medtech, diagnostics, lab instruments, sensors, wearables, drug-delivery devices, and any product with imported components, patent risk can become market-access risk.

Example – Masimo, Apple, and pulse oximetry. The U.S. International Trade Commission (ITC) ruled that certain Apple Watch models infringed Masimo patents on pulse-oximetry technology, and Apple later disabled the blood-oxygen feature on certain U.S. models in response. The lesson for life-science and medtech investors is direct: if a device, sensor, or component is imported, patent risk can determine whether the product can be sold in the United States at all.

Investor Diligence Should Change

For investors, the diligence question should evolve. The question is not only: has an FTO review been done? The better question is: how does the company keep FTO current?

Investors should ask whether the company has a process for monitoring patent risk as the business evolves – one that covers current products and planned variants, critical suppliers and imported components, manufacturing processes, software and data layers, key competitors, and pending applications and continuation activity in known patent families.

For investors, recurring FTO is not about eliminating all patent risk; it is about identifying material risk early enough to price it, negotiate around it, reserve for it, remediate it, or walk away.

That is where AI-enabled FTO may earn its keep. Not because it replaces legal judgment, but because it may help companies find risk early enough to make rational business decisions.

Conclusion

AI will not end patent litigation. It will not eliminate patent trolls or innocent infringement, and it will not replace patent lawyers, technical experts, or the judges and panels that decide these disputes.

But it may diminish patent surprise – and patent surprise is often where litigation leverage begins. A patent discovered early can be managed: designed around, licensed, challenged, monitored, reserved for, or disclosed. A patent discovered late can become a litigation weapon, an import ban, a financing complication, or an exit risk.

For life-science companies and investors, the practical lesson is the one this article began with.

Patent risk found early is a business issue. Patent risk found late becomes litigation leverage. AI is coming for patent surprise.

A Practical Next Step

AI will not make patent risk disappear. But it may make patent risk easier to find before it becomes litigation leverage.

For life-science companies, investors, and boards, that creates a practical question: is freedom-to-operate being treated as a one-time legal memo, or as a recurring risk-management discipline?

Daniel Holmander and Dr. Mike Morency work with life-science companies, investors, and technology-driven businesses on patent strategy, freedom-to-operate, IP diligence, portfolio quality, and commercialization risk.

If your company, portfolio company, or diligence target depends on life-science technology, medical devices, diagnostics, drug delivery, research tools, AI-enabled health technology, software, data, or imported components, we would be glad to discuss whether recurring FTO and patent-risk monitoring should be part of the strategy.

Selected Sources

• 35 U.S.C. § 271 – Patent infringement
• 35 U.S.C. § 284 – Damages
• 35 U.S.C. § 311 – Inter partes review
• 19 U.S.C. § 1337 – Unfair practices in import trade
• Ariosa Diagnostics v. Sequenom overview
• 10x Genomics overview and Bio-Rad litigation summary
• CRISPR patent dispute reporting
• AP report on Masimo / Apple Watch blood-oxygen feature
• BERT based freedom-to-operate patent analysis
• PANORAMA patent examination benchmark

Disclaimer

This article is for informational purposes only and does not constitute legal advice. The views expressed are those of the authors and do not necessarily reflect the views of their respective firm or clients.